Merck KGaA Buys Mirus Bio for $600 Million
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
MADISON, Wis., Aug. 3, 2023 /PRNewswire/ -- Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene therapy production, biopharmaceutical manufacturing, and research applications, today announced the launch of the RevIT AAV Enhancer. When added to the adeno-associated virus (AAV) production process, the novel enhancer increases AAV titers 2-4x in suspension 293 cells. It can be used in combination with the company's VirusGEN® transfection platform, as well as with polymer-only transfection reagents with minimal process optimization. As evidence of its broad applicability, the RevIT Enhancer increased titers in all AAV serotypes tested to date, and with a variety of cell lines and cell culture media commonly used to produce recombinant AAV.
Market Place
Share
Share
